In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Last month, Pfizer announced plans to yank its sickle cell drug Oxbryta from the market over safety concerns, leaving patients with one less treatment and unanswered questions about how to safely ...

In September 2024, Pfizer voluntarily withdrew large amounts of the sickle cell disease treatment medication Voxelotor, sold under the brand name Oxbryta, from worldwide markets. However ...

Oxbryta is manufactured as an oral therapy for patients with sickle cell disease. Hardiman began taking Oxbryta in 2020 under the belief that it would help manage his sickle cell disease.

Global Blood Therapeutics had developed Oxbryta that was used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease.

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

This electron microscope image provided by the National Institutes of Health in 2016 shows a blood cell altered by sickle cell disease, top. (National Center for Advancing Translational Sciences ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.